NADAC acquisition cost data for APTIOM 200 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
| 63402020230 | $35.72 | 2022-01-01 | Rx |
Generic: Eslicarbazepine Acetate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $103.2M | 82,695 | 8,912 | $33.12 |
| 2020 | $120.4M | 89,665 | 8,889 | $34.88 |
| 2021 | $124.0M | 86,184 | 8,334 | $36.96 |
| 2022 | $131.4M | 85,193 | 8,365 | $39.38 |
| 2023 | $142.0M | 84,935 | 8,348 | $42.46 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $13.2M | 8,478 | 853 |
| Texas | $12.3M | 7,737 | 875 |
| California | $11.3M | 5,850 | 705 |
| New York | $11.0M | 5,879 | 631 |
| Indiana | $6.9M | 4,736 | 427 |
| Michigan | $6.1M | 3,585 | 351 |
| Tennessee | $5.4M | 3,436 | 348 |
| New Jersey | $5.1M | 2,823 | 299 |
| Ohio | $5.0M | 2,844 | 279 |
| North Carolina | $4.8M | 2,692 | 277 |
| Alabama | $4.3M | 2,789 | 273 |
| Pennsylvania | $4.2M | 2,567 | 250 |
| Maryland | $3.9M | 2,283 | 268 |
| Missouri | $3.7M | 2,473 | 263 |
| Illinois | $3.7M | 2,603 | 236 |
| Georgia | $3.1M | 2,623 | 230 |
| Virginia | $2.8M | 1,540 | 190 |
| Kentucky | $2.8M | 1,716 | 167 |
| Mississippi | $2.6M | 1,871 | 176 |
| Louisiana | $2.6M | 1,820 | 181 |
| Arizona | $2.2M | 1,140 | 133 |
| Wisconsin | $2.1M | 998 | 102 |
| Massachusetts | $2.1M | 972 | 117 |
| Maine | $1.6M | 488 | 59 |
| Connecticut | $1.5M | 794 | 79 |
| Iowa | $1.5M | 943 | 83 |
| Utah | $1.4M | 735 | 81 |
| South Carolina | $1.4M | 730 | 85 |
| Arkansas | $1.3M | 750 | 70 |
| Idaho | $1.2M | 625 | 68 |
| Colorado | $1.2M | 622 | 75 |
| Oklahoma | $1.1M | 840 | 80 |
| West Virginia | $1.1M | 714 | 73 |
| Minnesota | $1.0M | 425 | 52 |
| Oregon | $989.6K | 484 | 47 |
| Kansas | $977.9K | 638 | 59 |
| Washington | $927.3K | 412 | 46 |
| Nevada | $726.8K | 570 | 54 |
| District of Columbia | $655.2K | 289 | 46 |
| New Hampshire | $351.7K | 199 | 22 |
| Rhode Island | $338.2K | 261 | 17 |
| Montana | $261.9K | 157 | 12 |
| New Mexico | $259.5K | 141 | 16 |
| Nebraska | $225.1K | 143 | 16 |
| Puerto Rico | $183.8K | 111 | 11 |
| Delaware | $180.3K | 96 | 14 |
| Hawaii | $138.2K | 72 | N/A |
| Vermont | $86.9K | 40 | N/A |
| Wyoming | $76.1K | 44 | N/A |
| North Dakota | $66.6K | 70 | N/A |
| South Dakota | $16.7K | 13 | N/A |
| Foreign Country | $11.9K | 16 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.